Press Release:

TUCSON, Ariz. – March 12, 2004 – SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Panel will discuss, make recommendations and vote on a Pre-Market Approval (PMA) for SynCardia’s CardioWest™ temporary Total Artificial Heart (TAH-t) on March 17, 2004.

The panel will review the CardioWest™ TAH-t’s indication for bridge-to-transplantation usage in cardiac transplant-eligible candidates at risk of imminent death from non-reversible biventricular failure. The CardioWest™ TAH-t completely replaces the patient’s diseased heart and immediately restores normal blood pressure and cardiac output, facilitating recovery of end-organ function, such as the kidney and liver. As a result, patients become better candidates for transplantation.

“We look forward to meeting with FDA advisory committee and we’re eagerly awaiting its feedback,” said Dr. Marvin J. Slepian, president and CEO, SynCardia. “The CardioWest™ TAH-t has been the subject of thoughtful design, engineering and testing. To date, it has successfully been implanted in more than 270 patients all over the world and earned a CE Mark in Europe. We’re confident that we are on course to make the CardioWest™ TAH-t a viable option for saving the lives of the many failing patients in need of or awaiting heart transplants.”

###

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 950 implants of the Total Artificial Heart, accounting for more than 230 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers and does not require expensive anti-rejection medication, which can cause subsequent complications. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

SynCardia Ranked #20 Among World's 50 Most Innovative Companies
In March 2011, Fast Company magazine ranked SynCardia #20 in its annual list of the "World's 50 Most Innovative Companies" for "giving mobility to artificial heart recipients." Weighing 13.5 pounds, SynCardia's Freedom® portable driver is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660